SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Cadus Pharmaceutical Corp. (KDUS)
KDUS 1.6000.0%Jul 2 5:00 PM EST

 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: scaram(o)uche who wrote (447)12/24/2000 12:50:49 PM
From: scaram(o)uche  Read Replies (1) of 1833
 
meanwhile, back at the ranch..... core patent issues, first claim sounding great.........

US6159705: Recombinant yeast cells for identifying receptor effectors

Inventor(s): Trueheart; Joshua , Concord, MA
Paul; Jeremy I. , Nyack, NY
Fuernkranz; Hans A. , San Jose, CA
Nathan; Debra , Mt. Kisco, NY
Holmes; Scott , Middlebury, CT

Applicant(s): Cadus Pharmaceutical Corporation, New York, NY

Issued/Filed Dates: Dec. 12, 2000 / Sept. 24, 1997

Application Number: US1997000936632

Abstract: The present invention makes available a rapid, effective assay for
screening and identifying pharmaceutically effective compounds that
specifically interact with and modulate the activity of a cellular
protein, e.g., a receptor or ion channel. The subject assay enables
rapid screening of large numbers of compounds to identify those
which act as an agonist or antagonist to the bioactivity of the cellular
protein. The subject assay is particularly amenable for identifying
surrogate ligands for receptors especially from small molecule or
peptide libraries or from peptides produced by an autocrine system.

What is claimed is:
1. An assay for identifying a compound that modulates a heterologous receptor expressed by a yeast
cell comprising:

i) providing a yeast cell which expresses a heterologous receptor which is functionally integrated
into an endogenous yeast signaling pathway, wherein said yeast cell comprises an endogenous
gene operatively linked to a heterologous promoter at the natural location of said endogenous
gene in said yeast cell, said promoter being responsive to signals produced by said yeast
signaling pathway;
ii) contacting the yeast cell with a test compound; and
iii) detecting an alteration in a signal produced by the endogenous yeast gene;

to thereby identify a compound that modulates the heterologous receptor.
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext